Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

NCT01111305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

NIH

Sponsor class

Conditions

Loiasis

Interventions

DRUG: Reslizumab
DRUG: Diethylcarbamazine
OTHER: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)